Arcus Biosciences, Inc. (RCUS)Healthcare | Biotechnology | Hayward, United States | NYSE
23.80 USD
+0.50
(2.146%)
⇧
(June 12, 2026, 4 p.m.
EDT)
After hours: 23.80 |
Hot Take ↕ | June 12, 2026, 8:41 p.m. EDT
The investment case for this biotech stock is currently defined by a stark tension between deteriorating fundamentals and a resilient balance sheet. While the company holds a substantial cash reserve relative to its debt, providing a safety net, its core business metrics are concerning, with revenue contracting sharply and profitability deeply negative. The long-term outlook remains neutral given these headwinds, though the stock price has rallied significantly from its 2025 lows, implying the market prices in a future catalyst. For the short term, the options market is pricing in fear, with put premiums far exceeding call premiums, and technicals showing weakness as the price trades below its fifty-day average. Investors should view this as a speculative hold rather than a conviction buy, waiting for clearer signs of revenue stabilization before increasing exposure. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.058141 |
| AutoETS | 0.060808 |
| AutoARIMA | 0.060809 |
| AutoTheta | 0.061403 |
| MSTL_79 | 0.070609 |
| MSTL_105 | 0.082653 |
| MSTL_79_105 | 0.096399 |
Forecast horizon: 60 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 0.10 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.395 |
| Excess Kurtosis | -0.64 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 21.565 |
| Revenue per Share | 2.067 |
| Market Cap | 2,993,401,088 |
| Forward P/E | -7.67 |
| Beta | 0.84 |
| Profit Margins | -156.36% |
| Website | https://arcusbio.com |
As of June 12, 2026, 8:41 p.m. EDT: Speculators are positioning defensively for a near-term decline, evidenced by significantly higher implied volatility on June 2026 puts compared to calls and heavy open interest on out-of-the-money puts at the $20 strike. Conversely, longer-dated calls show interest at the $35 strike, suggesting a bullish view on a potential recovery to higher levels eventually, though the immediate sentiment is skewed toward downside protection.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.6182618 |
| Address1 | 3,928 Point Eden Way |
| All Time High | 49.1 |
| All Time Low | 6.3 |
| Ask | 24.2 |
| Ask Size | 400 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 1,221,000 |
| Average Daily Volume3 Month | 1,163,369 |
| Average Volume | 1,163,369 |
| Average Volume10Days | 1,221,000 |
| Beta | 0.837 |
| Bid | 23.68 |
| Bid Size | 400 |
| Board Risk | 10 |
| Book Value | 4.175 |
| City | Hayward |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 23.8 |
| Current Ratio | 4.038 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,780,012,800 |
| Day High | 24.105 |
| Day Low | 23.29 |
| Debt To Equity | 21.565 |
| Display Name | Arcus Biosciences |
| Earnings Call Timestamp End | 1,778,013,000 |
| Earnings Call Timestamp Start | 1,778,013,000 |
| Earnings Timestamp | 1,778,011,200 |
| Earnings Timestamp End | 1,785,960,000 |
| Earnings Timestamp Start | 1,785,960,000 |
| Ebitda | -389,000,000 |
| Ebitda Margins | -1.64831 |
| Enterprise To Ebitda | -5.872 |
| Enterprise To Revenue | 9.68 |
| Enterprise Value | 2,284,401,152 |
| Eps Current Year | -3.48286 |
| Eps Forward | -3.10286 |
| Eps Trailing Twelve Months | -3.17 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 24.1392 |
| Fifty Day Average Change | -0.33920097 |
| Fifty Day Average Change Percent | -0.014051873 |
| Fifty Two Week Change Percent | 161.82619 |
| Fifty Two Week High | 28.72 |
| Fifty Two Week High Change | -4.92 |
| Fifty Two Week High Change Percent | -0.1713092 |
| Fifty Two Week Low | 7.91 |
| Fifty Two Week Low Change | 15.889999 |
| Fifty Two Week Low Change Percent | 2.0088496 |
| Fifty Two Week Range | 7.91 - 28.72 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,521,120,600,000 |
| Float Shares | 89,109,028 |
| Forward Eps | -3.10286 |
| Forward P E | -7.6703424 |
| Free Cashflow | -156,000,000 |
| Full Exchange Name | NYSE |
| Full Time Employees | 601 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,780,531,200 |
| Gross Margins | -1.2161 |
| Gross Profits | -287,000,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.29127002 |
| Held Percent Institutions | 0.72413003 |
| Implied Shares Outstanding | 125,773,162 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California. |
| Long Name | Arcus Biosciences, Inc. |
| Market | us_market |
| Market Cap | 2,993,401,088 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_325435188 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -369,000,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,993,401,255 |
| Number Of Analyst Opinions | 12 |
| Open | 23.5 |
| Operating Cashflow | -488,000,000 |
| Operating Margins | -7.88235 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 510 694 6200 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 23.8 |
| Post Market Time | 1,781,308,505 |
| Previous Close | 23.3 |
| Price Eps Current Year | -6.833464 |
| Price Hint | 2 |
| Price To Book | 5.7005982 |
| Price To Sales Trailing12 Months | 12.683903 |
| Profit Margins | -1.56356 |
| Quick Ratio | 3.967 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.46154 |
| Region | US |
| Regular Market Change | 0.5 |
| Regular Market Change Percent | 2.14592 |
| Regular Market Day High | 24.105 |
| Regular Market Day Low | 23.29 |
| Regular Market Day Range | 23.29 - 24.105 |
| Regular Market Open | 23.5 |
| Regular Market Previous Close | 23.3 |
| Regular Market Price | 23.8 |
| Regular Market Time | 1,781,294,402 |
| Regular Market Volume | 1,233,043 |
| Return On Assets | -0.23107 |
| Return On Equity | -0.69953 |
| Revenue Growth | -0.393 |
| Revenue Per Share | 2.067 |
| Sand P52 Week Change | 0.23177934 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 125,773,162 |
| Shares Percent Shares Out | 0.093100004 |
| Shares Short | 11,708,210 |
| Shares Short Previous Month Date | 1,777,507,200 |
| Shares Short Prior Month | 10,877,577 |
| Short Name | Arcus Biosciences, Inc. |
| Short Percent Of Float | 0.1532 |
| Short Ratio | 12.08 |
| Source Interval | 15 |
| State | CA |
| Symbol | RCUS |
| Target High Price | 47.0 |
| Target Low Price | 22.0 |
| Target Mean Price | 35.75 |
| Target Median Price | 34.5 |
| Total Cash | 822,000,000 |
| Total Cash Per Share | 6.536 |
| Total Debt | 113,000,000 |
| Total Revenue | 236,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.17 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 20.68575 |
| Two Hundred Day Average Change | 3.1142502 |
| Two Hundred Day Average Change Percent | 0.15055051 |
| Type Disp | Equity |
| Volume | 1,233,043 |
| Website | https://arcusbio.com |
| Zip | 94,545 |